Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 2, 2008, Pages 252-255

  Lontos, Steve ^a   Gow, Paul J ^a   Vaughan, Rhys B ^a   Angus, Peter W ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Ascites; Cirrhosis; Norfloxacin; Peritonitis; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; NORFLOXACIN;

ADULT; AGED; ARTICLE; BACTERIAL PERITONITIS; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA MULTIFORME; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PARANOIA; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SCORING SYSTEM;

EID: 39149102807     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.04926.x     Document Type: Article

References (17)

1. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J. Hepatol. 1993 18 : 353 8.
2. Almdal TP, Skinhoj P. Spontaneous bacterial peritonitis. Incidence, diagnosis, and prognosis. Scand. J. Gastroenterol. 1987 22 : 295 300.
3. Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology 1986 91 : 1343 6.
4. Tito L, Rimola A, Gines P et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988 8 : 27 31.
5. Andreu M, Sola R, Sitges-Serra A et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993 104 : 1133 8.
6. Singh N, Gayowski T, Yu VL et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis: a randomized trial. Ann. Intern. Med. 1995 122 : 595 8.
7. Gines P, Rimola A, Planas R et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990 12 : 716 24.
8. Grangé JD, Roulot D, Pelletier G et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J. Hepatol. 1998 29 : 430 6.
9. Novella M, Sola R, Soriano G et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997 25 : 532 6.
10. Rolachon A, Cordier L, Bacq Y et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995 22 : 1171 4.
11. Ortiz J, Vila MC, Soriano G et al. Infections caused by Escherichia coli resistant to norfloxacin in hospitalised cirrhotic patients. Hepatology 1999 29 : 1064 9.
12. Campillo B, Duperyon C, Richardet JP et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long term administration of norfloxacin. Clin. Infect. Dis. 1998 26 : 1066 70.
13. Dupeyron C, Mangeney N, Sedrati L et al. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob. Agents Chemother. 1994 38 : 340 4.
14. Soriano G, Guarner C, Teixido M et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991 100 : 477 81.
15. Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997 113 : 1289 94.
16. Younossi ZM, McHutchinson JG, Ganiats TG. An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. J. Hepatol. 1997 27 : 295 8.
17. Monthly Index of Medical Specialties (MIMS) Annual 2004. Sydney: CMPMedica Australia, 2004.